David Miles

Summary

Country: UK

Publications

  1. ncbi Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, London HA6 2RN, United Kingdom
    J Clin Oncol 29:83-8. 2011
  2. ncbi Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor
    Hannah M Simonds
    Mount Vernon Cancer Centre, Department of Oncology, Rickmansworth Road, Northwood, HA6 2RN, UK
    Expert Opin Biol Ther 7:487-91. 2007
  3. ncbi Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Middlesex HA6 2RN, UK
    Breast Cancer Res 11:208. 2009
  4. ncbi Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    J Clin Oncol 28:3239-47. 2010
  5. ncbi Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review
    David Miles
    Mount Vernon Cancer Centre, Northwood, UK
    Eur J Cancer 48:482-91. 2012
  6. ncbi Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles
    David Miles
    Mount Vernon Cancer Centre, Northwood, Middlesex, England
    Drugs 67:1800-1. 2007
  7. ncbi Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
    David Miles
    Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom
    Oncologist 16:1092-100. 2011
  8. ncbi Update on the use of aromatase inhibitors in early-stage breast cancer
    Georgios Kesisis
    Mount Vernon Cancer Centre, Rickmansworth, Northwood, Middlesex, HA6 2RN, UK
    Breast Cancer Res 11:211. 2009

Detail Information

Publications8

  1. ncbi Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials
    David Miles
    Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, London HA6 2RN, United Kingdom
    J Clin Oncol 29:83-8. 2011
    ....
  2. ncbi Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor
    Hannah M Simonds
    Mount Vernon Cancer Centre, Department of Oncology, Rickmansworth Road, Northwood, HA6 2RN, UK
    Expert Opin Biol Ther 7:487-91. 2007
    ..This review briefly summarises the use of trastuzumab in advanced breast cancer and describes recent studies of its use in the adjuvant setting...
  3. ncbi Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Rickmansworth Road, Middlesex HA6 2RN, UK
    Breast Cancer Res 11:208. 2009
    ..The novel agents bevacizumab and ixabepilone were recently approved for metastatic breast cancer, and numerous other agents are currently in clinical development that may contribute further valuable therapeutic options...
  4. ncbi Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    David W Miles
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    J Clin Oncol 28:3239-47. 2010
    ..5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial...
  5. ncbi Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review
    David Miles
    Mount Vernon Cancer Centre, Northwood, UK
    Eur J Cancer 48:482-91. 2012
    ..We also examine ongoing trials investigating capecitabine-bevacizumab combination therapy...
  6. ncbi Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles
    David Miles
    Mount Vernon Cancer Centre, Northwood, Middlesex, England
    Drugs 67:1800-1. 2007
  7. ncbi Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
    David Miles
    Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom
    Oncologist 16:1092-100. 2011
    ..Secondary endpoints included vaccine safety and immune response...
  8. ncbi Update on the use of aromatase inhibitors in early-stage breast cancer
    Georgios Kesisis
    Mount Vernon Cancer Centre, Rickmansworth, Northwood, Middlesex, HA6 2RN, UK
    Breast Cancer Res 11:211. 2009
    ..This review provides updates on the clinical trials of aromatase inhibitors in early breast cancer and tries to provide practical clinical guidance on their optimal use...